Everolimus for advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract: efficacy and safety from a RADIANT-4 subgroup analysis.
Authors
Singh, SCarnaghi, C
Buzzoni, R
Raderer, M
Lahner, H
Valle, Juan W
Voi, M
Pacaud, L
Lincy, J
Okita, N
Kulke, M
Strosberg, J
Yao, J
Pavel, M
Fazio, N
Affiliation
Sunnybrook Health Sciences Centre, Toronto,CanadaIssue Date
2017